Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive ALCL or ALK-positive unresectable IMT

Document first published:
Page updated:
Topic:
Publication type:

Crizotinib is not recommended to be available as a routinely commissioned treatment option for patients with relapsed or refractory ALK-positive ALCL or ALK-positive unresectable IMT within the criteria set out in the commissioning policy document.

Document

Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) or ALK-positive unresectable inflammatory myofibroblastic tumour (IMT)

Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) or ALK-positive unresectable inflammatory myofibroblastic tumour (IMT)

  • PDF
  • 176 KB
  • 5 pages

Summary

Published 16 July 2026.